This means that passive immunization with tau antibodies is really a viable therapeutic concentrate on and the CSF level of p-tau262/356 or on the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to watch tau therapeutics in clinical trials.They shown this connection with the two pathological specimens and by tau PET